GLP-1 drugs like Ozempic are proven effective for type 2 diabetes and weight management. Researchers are now exploring their potential to reduce heart, kidney, liver, and even Alzheimer’s disease risks. But experts, including obesity specialist Dr. Sean Wharton, warn against off-label use. He breaks down the latest research and what the future might hold.

For transcripts of The Dose, please visit: lnk.to/dose-transcripts. Transcripts of each episode will be made available by the next workday. For more episodes of this podcast, click this link.